Lianhuan Pharmaceutical announced that its holding subsidiary Changle Pharmaceutical recently received the “Drug Registration Certificate” for dagliflozin metformin sustained-release tablets approved and issued by the State Drug Administration. The drug is suitable for adult patients with type 2 diabetes to improve blood sugar control. In the first quarter of 2026, sales of dagliflozin and metformin sustained-release tablets in hospitals above level II nationwide reached 246.65,800 yuan. Changle Pharmaceutical invested about 9.63 million yuan in research and development of this drug, and the company and its subsidiaries received a total of 10 production approvals in 2026. This certification has enriched the product line, but is not expected to have a significant impact on recent results. Pharmaceutical production and sales are uncertain, so investors are reminded to be aware of the risks.

Lianhuan Pharmaceutical announced that its holding subsidiary Changle Pharmaceutical recently received the “Drug Registration Certificate” for dagliflozin metformin sustained-release tablets approved and issued by the State Drug Administration. The drug is suitable for adult patients with type 2 diabetes to improve blood sugar control. In the first quarter of 2026, sales of dagliflozin and metformin sustained-release tablets in hospitals above level II nationwide reached 246.65,800 yuan. Changle Pharmaceutical invested about 9.63 million yuan in research and development of this drug, and the company and its subsidiaries received a total of 10 production approvals in 2026. This certification has enriched the product line, but is not expected to have a significant impact on recent results. Pharmaceutical production and sales are uncertain, so investors are reminded to be aware of the risks.